SCHEMBL367913

SCHEMBL367913

NC(=O)c1ccc2ccccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.68
ALDH1A1 P00352 3/20 0.65
MAPT P10636 2/20 0.65
GAA P10253 1/20 0.65
CNR2 P34972 5/20 0.61
HDAC8 Q9BY41 1/20 0.61
KDM4E B2RXH2 3/20 0.56
NFKB1 P19838 2/20 0.56
RAB9A P51151 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
PIM1 P11309 1/20 0.55
KDM4C Q9H3R0 1/20 0.53
TSHR P16473 2/20 0.51
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
IKBKB O14920 1/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29540332 1.00 MGAM (0.68) MGAMALDH1A1MAPTGAACNR2
SCHEMBL5788458 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL29135887 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Hydrochloric Acid SCHEMBL3401098 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL5788456 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Ammonia Solution, Strong SCHEMBL29239526 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
SCHEMBL31434313 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Hydrochloric Acid SCHEMBL3400880 0.98 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2
Thiophene SCHEMBL3425727 0.89 MGAM (0.56) MGAMALDH1A1MAPTGAACNR2
Phthalic Acid SCHEMBL30909153 0.89 MGAM (0.66) MGAMALDH1A1MAPTGAACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371416-B2 Compounds for inhibition of fibroblast activation protein USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2025-07-29 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025058297-A1 COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING STAT3 INHIBITOR AND NICLOSAMIDE 국립암센터 2025-03-20 WO claimed
CN-119462501-A Preparation method of 2-quinolinamide compound promoted by acidic ionic liquid 内蒙古民族大学 2025-02-18 CN claimed
CN-119390688-A Quinoline amide derivative, and preparation method and application thereof 华南农业大学 2025-02-07 CN claimed
CN-119080882-A Eptifibatide derivative and preparation method thereof 山西医科大学 2024-12-06 CN claimed
CN-118666933-A Quinoline amide organogelator and preparation method and application thereof 上海应用技术大学 2024-09-20 CN claimed
CN-117794896-A Protease inhibitors for the treatment of coronavirus infections 斯克里普斯研究学院 2024-03-29 CN claimed
CN-115197240-B Quinoline compound, synthesis method, pharmaceutical composition and application 江南大学 2024-03-26 CN claimed
EP-3386511-B2 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-03-20 EP claimed
CN-1284878-A Drugs augmenting NKT cells FUJISAWA PHARMACEUTICAL CO (JP) 2001-02-21 CN claimed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO claimed
WO-2000062792-A2 COMPOSITIONS AND METHODS FOR CONTROLLING PESTS INSECT BIOTECHNOLOGY, INC. (US) 2000-10-26 WO claimed
EP-1042295-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-10-11 EP claimed
EP-0973767-A1 INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS Dupont Pharmaceuticals Company (US) 2000-01-26 EP claimed
US-5985867-A TREATING HIV INFECTION DUPONT PHARMACEUTICALS COMPANY (US) 1999-11-16 US claimed
WO-1999032450-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-01 WO claimed
WO-1998043969-A1 INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS DUPONT PHARMACEUTICALS COMPANY (US) 1998-10-08 WO claimed
US-5017636-A Also containing polyisoprene, natural rubber, butadiene-styrene copolymer, wear and heat resistance, resilience JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1991-05-21 US claimed
US-4616069-A REACTING THE ALKALI METAL OR ALKALINE EARTH METAL TERMINATED POLYMER WITH TIN COMPOUND AND ORGANIC COMPOUND HAVING AMIDE OR THIOAMIDE LINKAGES NIPPON ZEON CO., LTD. (JP) 1986-10-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371416-B2 Compounds for inhibition of fibroblast activation protein FAP, FIBP, APC MGAM 1756/4885ALDH1A1 1043/4885MAPT 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.